Publications and communications of Chantal LECHANTEUR

GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360
* These authors have contributed equally to this work.

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

VANDERMEULEN, M., Mohamed-Wais, M., ERPICUM, P., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., MAGGIPINTO, G., Jouret, F., Beguin, Y., & Detry, O. (2022). Infusion of allogeneic mesenchymal stromal cells after liver transplantation: Five-year follow-up. Liver Transplantation, 28, 636-646. doi:10.1002/lt.26323

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (2022). Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. Journal of Crohn's and Colitis, 16, 506-510. doi:10.1093/ecco-jcc/jjab154

MALAISE, O., PAULISSEN, G., DEROYER, C., Cirgea, F., Poulet, C., LECHANTEUR, C., Brondello, J.-M., DE SENY, D., & MALAISE, M. (December 2021). Influence des glucocorticoïdes sur les caractéristiques de la sénescence cellulaire dans les fibroblastes synoviaux d’origine arthrosique. Revue du Rhumatisme, 88 (S1), 157.

MALAISE, O.* , PAULISSEN, G.* , DEROYER, C., Ciregia, F., Poulet, C., NEUVILLE, S., PLENER, Z., DANIEL, C., Gillet, P., LECHANTEUR, C., Brondello, J.-M., DE SENY, D.* , & MALAISE, M.*. (16 November 2021). Influence of Glucocorticoids on Cellular Senescence Hallmarks in Osteoarthritic Fibroblast-like Synoviocytes. Journal of Clinical Medicine, 10 (22), 5331. doi:10.3390/jcm10225331
* These authors have contributed equally to this work.

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., MEUNIER, P., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., BEGUIN, Y., & LOUIS, E. (October 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study. Poster session presented at United European Gastroenterology.

VIEUJEAN, S., LOLY, J.-P., BOUTAFFALA, L., Pariente, B., REENAERS, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & LOUIS, E. (July 2021). Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical study. Poster session presented at 16th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2021 Virtual.

LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., & BEGUIN, Y. (2021). MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells, 10, 1320. doi:10.3390/cells10061320

VANDERMEULEN, M., ERPICUM, P., WEEKERS, L., BRIQUET, A., LECHANTEUR, C., Detry, O., Beguin, Y., & Jouret, F. (May 2020). Mesenchymal Stromal Cells in Solid Organ Transplantation. Transplantation, 104 (5), 923-936. doi:10.1097/TP.0000000000003077

HAUZEUR, J.-P., LECHANTEUR, C., BAUDOUX, E., De Maertelaer, V., Pather, S., Katz, R., Malaise, M., Ino, J., & Beguin, Y. (2020). Did Osteoblastic Cell Therapy Improve the Prognosis of Prefracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial. Clinical Orthopaedics and Related Research, 478, 1307-1315.

ERPICUM, P., WEEKERS, L., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., GREGOIRE, C., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., MAGGIPINTO, G., SOMJA, J., Pottel, H., Baron, F., Jouret, F., & BEGUIN, Y. (2019). Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney International, 95, 693-707. doi:10.1016/j.kint.2018.08.046

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

GREGOIRE, C., BRIQUET, A., PIRENNE, C., LECHANTEUR, C., LOUIS, E.* , & BEGUIN, Y.*. (November 2018). Allogeneic mesenchymal stromal cells for refractory luminal Crohn's disease: A phase I-II study. Digestive and Liver Disease, 50 (11), 1251-1255. doi:10.1016/j.dld.2018.08.015
* These authors have contributed equally to this work.

Servais, S., Baron, F., LECHANTEUR, C., SEIDEL, L., Selleslag, D., Maertens, J., BAUDOUX, E., Zachee, P., Van Gelder, M., Noens, L., Kerre, T., Lewalle, P., Schroyens, W., ORY, A., & Beguin, Y. (2018). Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget, 9 (29), 20590-20604. doi:10.18632/oncotarget.25020

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., Briquet, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & Beguin, Y. (July 2017). Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. Journal of Hepatology, 67 (1), 47-55. doi:10.1016/j.jhep.2017.03.001

WEEKERS, L., ERPICUM, P., DETRY, O., BONVOISIN, C., DELBOUILLE, M.-H., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (16 March 2017). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Paper presented at 24th Annual Meeting, Bruxelles, Belgium.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., GIET, O., BAUDOUX, E., Hannon, M., Baron, F., & BEGUIN, Y. (January 2017). UNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE. Transplant International, 30 (suppl 1), 8 (O12.

GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc.

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

HAUZEUR, J.-P., Tungouz, M., LECHANTEUR, C., Beguin, Y., BAUDOUX, E., de maertelaer, V., Pather, S., Katz, R., Ino, J., Egrise, D., Malaise, M., & Gangji, V. (October 2016). Ostéoblastes autologues (PREOB®) versus concentré de moelle autologue dans l’ostéonécrose de la tête fémorale : étude randomisée. Revue de Chirurgie Orthopédique et Traumatologie, 102, 73. doi:10.1016/j.rcot.2016.08.002

Erpicum, P., WEEKERS, L., DETRY, O., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (28 April 2016). Administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Paper presented at Annual Meeting of the BVN-SBN, Bruxelles, Belgium.

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice. Poster session presented at 31th General Meeting of the Belgian Hematological Society.

LECHANTEUR, C., BRIQUET, A., GIET, O., DELLOYE, O., BAUDOUX, E., & BEGUIN, Y. (2016). Clinical - scale expansion of mesenchymal stromal cells: a large banking experience. Journal of Translational Medicine, 14, 145-159. doi:10.1186/s12967-016-0892-y

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

WEEKERS, L., Erpicum, P., DETRY, O., BONVOISIN, C., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (2016). administration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up. Transplant International, 29 (Suppl 2), 13 -p6.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., HONORE, P., & BEGUIN, Y. (November 2015). Infusion of third-party mesenchymal stem cells after liver transplantation: a phase-1, open-label, clinical study. Transplant International, 28 (S4), 10/O27.

WEEKERS, L., ERPICUM, P., DETRY, O., JOURET, F., LECHANTEUR, C., DELBOUILLE, M.-H., BRIQUET, A., BAUDOUX, E., & BEGUIN, Y. (November 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. Transplant International, 28 (S4), 223-224/BO278.

WEEKERS, L., ERPICUM, P., DETRY, O., LECHANTEUR, C., BAUDOUX, E., JOURET, F., & BEGUIN, Y. (May 2015). Third-party mesenchymal stem cell infusion in kidney transplant recipient: 6-month safety interim analysis. American Journal of Transplantation, 15 (suppl 3).

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (April 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Journal of Hepatology, 62 (S2), 311 (P0052.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (27 March 2015). Infusion of third-party mesenchymal stromal cells after liver transplantation: a phase 1, open-label, clinical study. Poster session presented at 22nd Annual Meeting, Brussels, Belgium.

DETRY, O., VANDERMEULEN, M., DELBOUILLE, M.-H., DE ROOVER, A., SOMJA, J., BLETARD, N., BRIQUET, A., LECHANTEUR, C., & BEGUIN, Y. (March 2015). Infusion of third-party mesenchymal stream cells after liver transplantation: a phase-1, open-label, clinical study. Acta Gastro-Enterologica Belgica, 78 (1), 29.

Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597

DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56.

Hannon, M., LECHANTEUR, C., Lucas, S., Somja, J., Seidel, L., Belle, L., Bruck, F., BAUDOUX, E., GIET, O., Chantillon, A.-M., Delvenne, P., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (17 June 2014). Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. Transfusion, 54 (February), 353-363. doi:10.1111/trf.12279

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

BRIQUET, A., GREGOIRE, C., Comblain, F., Servais, L., Zeddou, M., LECHANTEUR, C., & Beguin, Y. (2014). Human bone marrow, umbilical cord or liver mesenchymal stromal cells fail to improve liver function in a model of CCl4-induced liver damage in NOD/SCID/IL-2Ry(null) mice. Cytotherapy, 16, 1511-1518. doi:10.1016/j.jcyt.2014.07.003

Erpicum, P., DETRY, O., WEEKERS, L., BONVOISIN, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2014). Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion. Nephrology Dialysis Transplantation, 29, 1487-1493. doi:10.1093/ndt/gft538

LECHANTEUR, C., Baila, S., Janssen, M. E., GIET, O., BRIQUET, A., BAUDOUX, E., & Beguin, Y. (2014). Large-Scale Clinical Expansion of Mesenchymal Stem Cells in the GMP-Compliant, Closed Automated Quantum® Cell Expansion System: Comparison with Expansion in Traditional T-Flasks. Journal of Stem Cell Research and Therapy, 4 (8), 1000222. doi:10.4172/2157- 7633.1000222

MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068

VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418

DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., SQUIFFLET, J.-P., Honoré, P., DELVENNE, P., MEURISSE, M., BAUDOUX, E., & BEGUIN, Y. (30 May 2013). INFUSION OF THIRD-PARTY MESENCHYMAL STEM CELLS (MSC) AFTER KIDNEY AND LIVER TRANSPLANTATION: A PHASE I-II, OPEN-LABEL, CLINICAL STUDY (EudraCT 2011-001822-81 & NCT01429038). Poster session presented at 13eme rencontre de Beaune, Beaune, France.

Bruck, F.* , Belle, L.* , LECHANTEUR, C., de Leval, L., Hannon, M., DUBOIS, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., Beguin, Y., BRIQUET, A.* , & Baron, F.*. (March 2013). Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy, 15 (3), 267-279. doi:10.1016/j.jcyt.2012.09.003
* These authors have contributed equally to this work.

BRIQUET, A., HALLEUX, A., LECHANTEUR, C., & BEGUIN, Y. (2013). Neuropeptides to replace serum in cryopreservation of mesenchymal stromal cells ? Cytotherapy, 15, 1385-1394. doi:10.1016/j.jcyt.2013.06.012

Hannon, M., LECHANTEUR, C., Somja, J., Lucas, S., Belle, L., Bruck, F., Baudoux, E., Beguin, Y., Humblet-Baron, S., & Baron, F. (2013). Infusion of CliniMACS (Myltenyi Biotec) Enriched Regulatory T Cells Delays Experimental Xenogeneic Graft-versus-Host Disease. Belgian Journal of Hematology, Abstracts book (Supplement of 28th General Meeting of the Belgian Hematological Society), 15.

Hauzeur, J.-P., Bernard, C., Egrise, D., Kurth, W., Van Cauwenberge, H., LECHANTEUR, C., Gillet, P., Beguin, Y., MALAISE, M., & HUSTINX, R. (2013). (111)Indium-oxine labelling for evaluating the homing process of autologous osteoblasts implanted percutaneously in atrophic nonunion fractures. International Orthopaedics, 37 (1), 131-6. doi:10.1007/s00264-012-1719-y

DETRY, O., DELBOUILLE, M.-H., LECHANTEUR, C., SOMJA, J., DE ROOVER, A., WEEKERS, L., DELVENNE, P., BAUDOUX, E., & BEGUIN, Y. (19 October 2012). Infusion of third party mesenchymal stem cells (MSC) after kidney and liver transplantation: a phase I-II, open-label, clinical study. Paper presented at 4th Expert meeting, Barcelona, Spain.

Bruck, F., de Leval, L., Belle, L., LECHANTEUR, C., Hannon, M., BRIQUET, A., Dubois, S., CASTERMANS, E., Humblet-Baron, S., Rahmouni, S., BEGUIN, Y., & BARON, F. (2012). Bone marrow-derived mesenchymal stromal cells failed to prevent experimental xenogeneic graft-versus-host disease. Poster session presented at Belgian Hematological Society General Annual Meeting.

BERNARD, C., HAUZEUR, J.-P., LECHANTEUR, C., VAN CAUWENBERGE, H., BEGUIN, Y., MALAISE, M., KURTH, W., GILLET, P., & HUSTINX, R. (2011). Evaluation of the homing process in the treatment of atrophic nonunion fractures by percutaneous autologous osteoblast cell implantation. Journal of Nuclear Medicine, 52 (SUPPL), 510.

Baron, F., Lechanteur, C., Willems, E., Bruck, F., Baudoux, E., Seidel, L., Vanbellinghen, J.-F., Hafraoui, K., LEJEUNE, M., Gothot, A., Fillet, G., & Beguin, Y. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16 (6), 838-47. doi:10.1016/j.bbmt.2010.01.011

Zeddou, M., Briquet, A., Relic, B., Josse, C., Malaise, M., Gothot, A., Lechanteur, C., & Beguin, Y. (2010). The umbilical cord matrix is a better source of mesenchymal stem cells (MSC) than the umbilical cord blood. Cell Biology International, 34 (7), 693-701. doi:10.1042/CBI20090414

Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning. Paper presented at 35th EBMT Annual Meeting.

Robe, P., Nguyen-Khac, M.-T., Lambert, F., Lechanteur, C., Jolois, O., Ernst-Gengoux, P., Rogister, B., & Bours, V. (January 2007). Sufasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. International Journal of Oncology, 30 (1), 283-290. doi:10.3892/ijo.30.1.283

Lechanteur, C., Jacobs, N., Greimers, R., Benoit, V., Deregowski, V., Chariot, A., Merville, M.-P., & Bours, V. (03 March 2005). Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis. Oncogene, 24 (10), 1788-1793. doi:10.1038/sj.onc.1208436

Lechanteur, C., Delvenne, P., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J., Merville, M.-P., & Bours, V. (September 2000). Combined Suicide and Cytokine Gene Therapy for Peritoneal Carcinomatosis. Gut, 47 (3), 343-8. doi:10.1136/gut.47.3.343

Lechanteur, C., Moutschen, M., Princen, F., Lopez, M.-J., Franzen, E., Gielen, J., Bours, V., & Merville, M.-P. (May 2000). Antitumoral Vaccination with Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-12-Expressing Dhd/K12 Colon Adenocarcinoma Cells. Cancer Gene Therapy, 7 (5), 676-82. doi:10.1038/sj.cgt.7700152

Bentires-Alj, M., Hellin, A.-C., Lechanteur, C., Princen, F., Lopez Y Cadenas, M., Fillet, G., Gielen, J.-L., Merville, M.-P., & Bours, V. (January 2000). Cytosine Deaminase Suicide Gene Therapy for Peritoneal Carcinomatosis. Cancer Gene Therapy, 7 (1), 20-6. doi:10.1038/sj.cgt.7700093

Princen, F., Lechanteur, C., Lopez, M.-J., Gielen, J., Bours, V., & Merville, M.-P. (2000). Similar Efficiency of DNA-Liposome Complexes and Retrovirus-Producing Cells for Hsv-Tk Suicide Gene Therapy of Peritoneal Carcinomatosis. Journal of Drug Targeting, 8 (2), 79-89. doi:10.3109/10611860008996854

Princen, F., Robe, P., Lechanteur, C., Mesnil, M., Rigo, J.-M., Gielen, J., Merville, M.-P., & Bours, V. (November 1999). A Cell Type-Specific and Gap Junction-Independent Mechanism for the Herpes Simplex Virus-1 Thymidine Kinase Gene/Ganciclovir-Mediated Bystander Effect. Clinical Cancer Research, 5 (11), 3639-44.

Princen, F., Lechanteur, C., Lopez Y Cadenas, M., Rocoux, G., Detroz, B., Gielen, J.-L., Fillet, G., Merville, M.-P., & Bours, V. (August 1998). Repeated Cycles of Retrovirus-Mediated Hsvtk Gene Transfer Plus Ganciclovir Increase Survival of Rats with Peritoneal Carcinomatosis. Gene Therapy, 5 (8), 1054-60. doi:10.1038/sj.gt.3300710

Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J., Bours, V., & Merville, M.-P. (1998). Hsv-1 Thymidine Kinase Gene Therapy for Peritoneal Carcinomatosis. Advances in Experimental Medicine and Biology, 451, 115-9. doi:10.1007/978-1-4615-5357-1_18

Lechanteur, C., Princen, F., Lo Bue, S., Detroz, B., Fillet, G., Gielen, J.-L., Bours, V., & Merville, M.-P. (November 1997). Hsv-1 Thymidine Kinase Gene Therapy for Colorectal Adenocarcinoma-Derived Peritoneal Carcinomatosis. Gene Therapy, 4 (11), 1189-94. doi:10.1038/sj.gt.3300520

Charlier, C., Bruyneel, E., Lechanteur, C., Bracke, M., Mareel, M., & Castronovo, V. (19 December 1996). Enhancement of Tamoxifen-Induced E-Cadherin Function by Ca2+ Channel Antagonists in Human Breast Cancer Mcf7/6 Cells. European Journal of Pharmacology, 317 (2-3), 413-6. doi:10.1016/S0014-2999(96)00816-3